GYG Gyg Plc

RNS Number:4973W
Gyrus Group PLC
28 May 2002

Embargoed for Release, Tuesday 28 May 2002 - 7.00am (BST)





             GYRUS GROUP PLC FOCUSES ON PROSTATE CANCER SURGERY AT

                     AMERICAN UROLOGY ASSOCIATION MEETING





READING, UK - Gyrus Group PLC, (GYG.L "Gyrus" or "the Group") a world leader in
the management of tissue using less traumatic techniques has introduced a new
line of products for the world's urologists at this year's meeting of the
American Urology Association (AUA) meeting in Orlando, Florida.



Gyrus has introduced the first of a new range "Zip" instruments which uniquely
combine the vessel sealing and tissue vaporization capability of the
PlasmaKinetic (PK) Tissue Management System in a single instrument.



The PK Zip WingTM Cutting Dissector provides the surgeon with an instrument
designed to meet the complexity of laparoscopic urological procedures performed
on the kidneys, bladder and prostate, often for cancer.



The new instrument eliminates the need for multiple instrument exchanges,
provides fast effective hemostasis and thereby reduces the time to complete
these complex less invasive procedures.



The meeting also provides the venue for introducing the PK SealTM "Angled
Variants", designed for use during open radical prostatectomy for cancer where
haemostasis and preservation of function are particularly important.



Gyrus estimates that these introductions increase its annual market opportunity
in urology by $110M.



Also released at the AUA, were the results of a comparative trial of the PK
System against conventional resection in the treatment benign prostatic
hypertrophy performed at the Tulane University Medical Centre.  The average
length of stay for the PK treatment group was 0.5 days compared to 1.2 days for
the control, despite the PK group having significantly larger prostate glands.
Overall, the cost of treatment using the PK system was $1,138 less than for
conventional resection.



"These products have been developed specifically for less traumatic excision of
a variety of cancers that may arise in the urinary system, of which prostatic
cancer is now forecast to takeover as the leading cancer risk in the male
population," said Mark Goble, Gyrus Group Managing Director. "This continues our
strategic mission of providing a robust technology platform for surgeons
pursuing advanced, cost effective, treatment options for a growing range of
today's healthcare needs."





Background & Market Update



Urological applications for new Gyrus products



With a growing acceptance and clinical endorsement of Gyrus' PK system for
treatment of benign enlargement of the prostate, these new instruments provide
additional procedure applications in urological surgery, thereby increasing the
potential disposable revenue from the installed base of generators.  It clearly
demonstrates the Group's strategy of leveraging niche market penetration to
broaden the market opportunity for its products.



The PK Zip ("Zip" for speed and ease of use) Wing features fine, controlled
tissue vaporisation and precise vessel sealing in a multifunctional instrument.
The PK Zip Wing works in conjunction with Gyrus Medical's PK (PlasmaKineticTM)
Generator, utilizing the company's exclusive Zip and Vapor Pulse Coagulation
(VPC) technologies to intelligently deliver optimal energy during the less
traumatic management of tissues during advanced surgical procedures.  Combined
with the advanced technology of the PK Generator and line of other PK
instruments, Gyrus is the only company to offer urologists a complete system of
devices for transurethral, laparoscopic and open procedures.



The PK Seal technology works by utilizing VPC to deliver high levels of pulsed
energy to tissue.  The pulsed energy coagulates tissue by creating vapor pockets
within the tissue, resulting in controlled, repeatable vessel sealing.  The
technology combines the safety of bipolar electrosurgery with additional
clinical and ease-of-use performance enhancements.



Notes to editors



About Gyrus

Gyrus Group PLC is a growing medical technology company with principle UK
operations based in Cardiff and Reading. The Group comprises four operational
units: Gyrus Medical Inc. Gyrus Medical Ltd., Gyrus International Ltd. and Gyrus
ENT.



"Meet the Management" day

On Wednesday June 26th Gyrus Group PLC will hold their first "Meet the
Management" day for financial analysts and members of the media.  It will be
held at The City Media Centre of The London Stock Exchange, London EC2N 1HP.





Enquiries:


Gyrus Group PLC

Mark Goble, Managing Director                                 Tel: 01189 219720

Christian Williams, Director of Corporate Communications


Fleishman Hillard Public Relations                            Tel: 0207 306 9000

Jennifer Ryan


Financial Dynamics                                            Tel: 0207 831 3113

Edward Bridges/Sarah Manners





                      This information is provided by RNS
            The company news service from the London Stock Exchange

Gyg (LSE:GYG)
Historical Stock Chart
Von Jun 2024 bis Jul 2024

Gyg (LSE:GYG)
Historical Stock Chart
Von Jul 2023 bis Jul 2024